Founded with the mission to advance the field of regenerative medicine, Excellos is a pioneering developer and manufacturer of cell and gene therapies. The company offers a range of services including customized cell collections, cell isolation, cell characterization, and GMP manufacturing. Excellos focuses on providing high-quality, regulatory-compliant products such as LRS chambers, leukopak, and isolated cells from peripheral and cord blood to support research and clinical applications.
Excellos has garnered attention from notable figures in the biotech industry and has attracted investment from key stakeholders committed to advancing medical science. The company’s achievements include successful development and commercialization of critical cell therapy products, contributing significantly to advancements in regenerative medicine. Excellos continues to impact the market by enabling groundbreaking therapies that promise to transform patient care and treatment outcomes globally.
